ReviewPediatric nephrology (Berlin, Germany)2005
Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
Review in Pediatric nephrology (Berlin, Germany), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 94 citations in OpenAlex.
- Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.International journal of molecular sciences · 2022Review
- A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo.Nature communications · 2021Article
- Review
- Management of a Patient with Tuberous Sclerosis with Urological Clinical Manifestations.Medicina (Kaunas, Lithuania) · 2020Article
- Article
- Early manifestations of renal disease in patients with tuberous sclerosis complex.International journal of nephrology and renovascular disease · 2017Article
- Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.The American journal of pathology · 2016Article
- Tuberous sclerosis complex-associated renal angiomyolipomas: A single center study of 17 consecutive cases.Oncology letters · 2016Article
- Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation.Cancer research · 2016Article
- CT-imaging features of renal epithelioid angiomyolipoma.World journal of surgical oncology · 2015Article
- Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report.World journal of surgical oncology · 2015Article
- Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.Pediatric radiology · 2015Article
- The bigger the better: determining nephron size in kidney.Pediatric nephrology (Berlin, Germany) · 2014Review
- Bilateral renal cell carcinoma in a paediatric patient with tuberous sclerosis complex.BMJ case reports · 2013Article
- Clinical and molecular insights into tuberous sclerosis complex renal disease.Pediatric nephrology (Berlin, Germany) · 2011Review
- Evidence for population variation in TSC1 and TSC2 gene expression.BMC medical genetics · 2011Article
- Tuberous sclerosis complex: neurological, renal and pulmonary manifestations.Neuropediatrics · 2010Review
- mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.Lymphatic research and biology · 2010Article
- The tuberous sclerosis complex.Annals of the New York Academy of Sciences · 2010Review
- Emerging evidence of a link between the polycystins and the mTOR pathways.PathoGenetics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The renal manifestations of tuberous sclerosis complex (TSC) are remarkably diverse, including polycystic kidney disease, oncocytomas, renal cell carcinomas, and both benign and malignant angiomyolipomas. All of these occur in children as well as adults with TSC. Benign angiomyolipomas, which can cause spontaneous life-threatening hemorrhage, are by far the most prevalent and the greatest source of morbidity. What is particularly unusual about TSC, setting it apart from virtually all other inherited forms of renal disease, is the abnormalities of both mesenchymal cells (angiomyolipomas) and epithelial cells (cysts, oncocytomas, and carcinomas). Recently, the TSC1/TSC2 protein complex was shown to inhibit the kinase mTOR (mammalian target of rapamycin). This places TSC1/TSC2 at center stage in signaling pathways that regulate cell growth. Furthermore, recent advances in TSC1/TSC2 signaling open the door for targeted therapy for TSC patients. Here, we will address the genetic, cellular and biochemical mechanisms that may contribute to the unusually broad spectrum of renal disease in cells with TSC1 or TSC2 mutations, and consider how the TSC signaling pathways may be linked to other renal diseases such as polycystic kidney disease and renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.